TABLE 2.
Licensing deals from co-developed in vivo genome editing and regulation CNS assets (excluding AskBio/Editas) https://investor.sangamo.com/news-releases/news-release-details/sangamo-announces-global-collaboration-novartis-develop-genomic.
| Licensee | Licensor | Phase | Indication | Upfront ($m) | Milestone Payments (Up to $m) | Year |
| Pfizer | Sangamo Therapeutics | Pre-clinical | ALS/FTLD | 12 | 150 | 2018 |
| Takeda Pharmaceutical Company | Sangamo Therapeutics | Pre-clinical | Huntington’s | Unknown | Unknown | 2019 |
| Biogen | Sangamo Therapeutics | Pre-clinical | Tauopathies, Synucleinopathies (Inc., Parkinson’s disease), a neuromuscular target and up to nine other undisclosed neurological indication | 350 | 2,370 | 2020 |
| Novartis | Sangamo Therapeutics | Pre-clinical | Neurodevelopmental Disorders (Inc., Autism Spectrum Disorder) | 75 | 720 | 2020 |